{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T11:09:09Z","timestamp":1749640149016},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>This article discusses key considerations regarding ticagrelor\u2019s reported effect on heparin-induced thrombocytopenia functional assays, such as literature gaps and possible management strategies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Limited data indicate that ticagrelor may induce false-negative results in functional assays used in the diagnosis of heparin-induced thrombocytopenia. False-negative functional assays for heparin-induced thrombocytopenia could have catastrophic consequences. The manufacturer labeling of ticagrelor now includes a warning for this potential drug-laboratory interaction. This article suggests areas that would benefit from further research and strategies in navigating this possible interaction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Clinicians should exercise caution when evaluating functional assays for heparin-induced thrombocytopenia in patients receiving ticagrelor. This article offers suggestions for future areas of research and potential management strategies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae040","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T01:14:35Z","timestamp":1708132475000},"page":"488-493","source":"Crossref","is-referenced-by-count":1,"title":["Key considerations in navigating ticagrelor\u2019s reported effect on heparin-induced thrombocytopenia functional assays in a landscape of limited data"],"prefix":"10.1093","volume":"81","author":[{"given":"Genene","family":"Salman","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, Marshall B. Ketchum University , Fullerton, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman J","family":"Johannesmeyer","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California , Irvine, Irvine, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J","family":"Breen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, St. Jude Medical Center , Fullerton, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"issue":"22","key":"2024061112411966400_CIT0001","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"2024061112411966400_CIT0002","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMcp1411910","article-title":"Clinical practice: heparin-induced thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2024061112411966400_CIT0003","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V72.3.925.bloodjournal723925","article-title":"Heparin-induced thrombocytopenia: laboratory studies","volume":"72","author":"Kelton","year":"1988","journal-title":"Blood"},{"issue":"8","key":"2024061112411966400_CIT0004","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","article-title":"Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis","volume":"106","author":"Martel","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2024061112411966400_CIT0005","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.06-2109","article-title":"The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital","volume":"131","author":"Smythe","year":"2007","journal-title":"Chest"},{"issue":"1","key":"2024061112411966400_CIT0006","first-page":"132","article-title":"Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients","volume":"94","author":"Greinacher","year":"2005","journal-title":"Thromb Haemost"},{"issue":"2","key":"2024061112411966400_CIT0007","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.amjcard.2017.04.028","article-title":"Incidence and outcomes of heparin-induced thrombocytopenia in patients undergoing transcatheter aortic valve replacement","volume":"120","author":"Telila","year":"2017","journal-title":"Am J Cardiol"},{"issue":"20","key":"2024061112411966400_CIT0008","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1182\/blood-2012-07-443051","article-title":"Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis","volume":"120","author":"Cuker","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2024061112411966400_CIT0009","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1378\/chest.12-2712","article-title":"Improving clinical interpretation of the anti-platelet factor 4\/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, stratum-specific likelihood ratios, and Bayes theorem","volume":"144","author":"Raschke","year":"2013","journal-title":"Chest"},{"issue":"4","key":"2024061112411966400_CIT0010","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/molecules22040617","article-title":"Functional assays in the diagnosis of heparin-induced thrombocytopenia: a review","volume":"22","author":"Minet","year":"2017","journal-title":"Molecules"},{"issue":"8","key":"2024061112411966400_CIT0011","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/jth.13758","article-title":"Clinical effectiveness of a Bayesian algorithm for the diagnosis and management of heparin-induced thrombocytopenia","volume":"15","author":"Raschke","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2024061112411966400_CIT0012","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/ijlh.12993","article-title":"Laboratory diagnosis of heparin-induced thrombocytopenia","volume":"41","author":"Warkentin","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"8","key":"2024061112411966400_CIT0013","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1538-7836.2008.03025.x","article-title":"Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays","volume":"6","author":"Warkentin","year":"2008","journal-title":"J Thromb Haemost"},{"key":"2024061112411966400_CIT0014","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.thromres.2017.03.010","article-title":"Performance characteristics of an automated latex immunoturbidimetric assay (HemosIL HIT-Ab(PF4-H)) for the diagnosis of immune heparin-induced thrombocytopenia","volume":"153","author":"Warkentin","year":"2017","journal-title":"Thromb Res"},{"issue":"11","key":"2024061112411966400_CIT0015","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood.2019003582","article-title":"Ticagrelor causes false-negative functional tests for heparin-induced thrombocytopenia","volume":"135","author":"Eekels","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2024061112411966400_CIT0016","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/jcph.2296","article-title":"False-negative functional tests for heparin-induced thrombocytopenia in patients receiving ticagrelor: a case report","volume":"63","author":"Mo","year":"2023","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"2024061112411966400_CIT0017","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/blood.V91.2.549","article-title":"Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation\/aggregation induced by sera from heparin-induced thrombocytopenia patients","volume":"91","author":"Polg\u00e1r","year":"1998","journal-title":"Blood"},{"key":"2024061112411966400_CIT0018","author":"Brilinta (ticagrelor) tablets, for oral use"},{"key":"2024061112411966400_CIT0019","author":"Mayo Clinic Laboratories"},{"issue":"4","key":"2024061112411966400_CIT0020","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11239-016-1381-0","article-title":"Heparin-induced thrombocytopenia: reducing misdiagnosis via collaboration between an inpatient anticoagulation pharmacy service and hospital reference laboratory","volume":"42","author":"Burnett","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2024061112411966400_CIT0021","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11239-019-02011-8","article-title":"Pharmacist involvement in clinical assessment and laboratory testing for heparin-induced thrombocytopenia","volume":"50","author":"Condon","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2024061112411966400_CIT0022","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2013.08.003","article-title":"Thrombocytopenia","volume":"25","author":"Greenberg","year":"2013","journal-title":"Crit Care Nurs Clin North Am"},{"issue":"4","key":"2024061112411966400_CIT0023","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/09537104.2021.1961707","article-title":"Severe thrombocytopenia in adults undergoing extracorporeal membrane oxygenation is predictive of thrombosis","volume":"33","author":"Kohs","year":"2022","journal-title":"Platelets"},{"issue":"4","key":"2024061112411966400_CIT0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa169","article-title":"A case report of absolute thrombocytopenia with ticagrelor","volume":"4","author":"Khan","year":"2020","journal-title":"Eur Heart J Case Rep"},{"issue":"5","key":"2024061112411966400_CIT0025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ijlh.12853","article-title":"A novel diagnostic algorithm for heparin-induced thrombocytopenia","volume":"40","author":"Zheng","year":"2018","journal-title":"Int J Lab Hematol"},{"issue":"25","key":"2024061112411966400_CIT0026","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"2024061112411966400_CIT0027","author":"Plavix (clopidogrel sulfate) tablets, for oral use"},{"issue":"2","key":"2024061112411966400_CIT0028","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40262-013-0105-2","article-title":"Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases","volume":"53","author":"Kara\u017aniewicz-\u0141ada","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"2024061112411966400_CIT0029","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1592\/phco.29.9.1089","article-title":"Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor","volume":"29","author":"Dobesh","year":"2009","journal-title":"Pharmacotherapy"},{"issue":"3","key":"2024061112411966400_CIT0030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"2024061112411966400_CIT0031","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40256-021-00491-9","article-title":"Cost-consequence analysis of using cangrelor in high angiographic risk percutaneous coronary intervention patients: a US hospital perspective","volume":"22","author":"Jensen","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"issue":"11","key":"2024061112411966400_CIT0032","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2024061112411966400_CIT0033","author":"Effient (prasugrel) tablets"},{"key":"2024061112411966400_CIT0034","author":"Centers for Disease Control and Prevention"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae040\/56814607\/zxae040.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/12\/488\/58196437\/zxae040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/12\/488\/58196437\/zxae040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T21:46:12Z","timestamp":1718142372000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/81\/12\/488\/7607923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,2,14]]},"published-print":{"date-parts":[[2024,6,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae040","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,15]]},"published":{"date-parts":[[2024,2,14]]}}}